<DOC>
	<DOCNO>NCT02053116</DOCNO>
	<brief_summary>A Phase 2a study evaluate effect investigational compound administer 200 mg , twice daily ( BID ) , 6 week , canagliflozin , adult subject Type 2 Diabetes Mellitus ( T2DM ) .</brief_summary>
	<brief_title>A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Patients Type 2 Diabetes Mellitus treat metformin dose great equal 1000 mg least 3 month willing switch canagliflozin metformin duration study Hemoglobin A1c 710 % screening . Body Mass Index least 25 kg/m2 . Compliant study drug administration runin period throughout trial . Patients fast triglyceride great 500 mg/dL screening . History certain diabetic complication cardiac problem .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>